Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Audits Fall To NDA Sponsors; First Reviews Entail Rejection/Re-Review

Executive Summary

FDA will be relying on NDA sponsors to conduct audits of pharmacies and providers rather than policing compliance with REMS (risk evaluation and mitigation strategies) on its own, Sidley Austin partner Coleen Klasmeier suggested during a Nov. 13 webinar

You may also be interested in...

Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed

Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.

The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months

FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March

FDA: BioDelivery Sciences Should Improve “Safe Use” REMS Provisions For Oral Fentanyl Approval

Onsolis “complete response” letter is “as close to approval as one can get without having it,” BDSI CEO says.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts